Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
On Oct. 16, 2026, NAGE is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
Niagen Bioscience, Inc. is a small-cap company with a market capitalization of $197M. It ranks number 10 by market capitalization among the 29 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast. Its ROE of 19.4% is the highest of the 16 peers that report one.
For NAGE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 59.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, NAGE included.
Follow NAGE free90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
| Metric | NAGE | Rank |
|---|---|---|
| Market Cap | $197M | 10/29 |
| P/E Ratio | 14.65x | 3/6 |
| P/B Ratio | 2.39x | 5/13 |
| EPS | $0.17 | – |
| Book Value/Share | $1.04 | – |
| Revenue/Share | $1.63 | – |
| Metric | NAGE | Rank |
|---|---|---|
| ROE | 19.4% | 1/16 |
| ROA | 15.0% | 2/25 |
| ROIC | 11.6% | 5/21 |
| Gross Margin | 64.2% | 5/23 |
| Operating Margin | 8.2% | 3/24 |
| Net Margin | 12.4% | 3/22 |
| EBT Margin | 13.2% | 3/25 |
| Tax Rate | 6.1% | – |
| Metric | NAGE | Rank |
|---|---|---|
| Current Ratio | 6.50x | 3/29 |
| Quick Ratio | 5.13x | 2/26 |
| D/E Ratio | 0.29x | 13/17 |
| Financial Leverage | 1.29x | 14/17 |
| Interest Coverage | 4086.0x | 1/22 |
| Working Capital | $83M | 9/29 |
| Metric | NAGE | Rank |
|---|---|---|
| Operating Cash Flow | $6M | 9/30 |
| OCF Growth YoY | -72.0% | 8/11 |
| Metric | NAGE | Rank |
|---|---|---|
| Asset Turnover | 1.21x | 5/17 |
| Receivables Turnover | 15.0x | 9/16 |
| Inventory Turnover | 2.2x | 16/21 |
| Fixed Assets Turnover | 103.5x | 3/17 |
| Days Sales Outstanding | 24 days | 8/16 |
| Days Inventory | 163 days | 5/20 |
| Payables Period | 75 days | 4/18 |
| Cash Conversion Cycle | 113 days | 5/12 |
| Metric | NAGE | Rank |
|---|---|---|
| Total Revenue | $129M | 12/18 |
| Operating Income | $11M | 3/28 |
| Net Income | $16M | 2/25 |
| R&D Expense | $6M | 4/9 |
| SG&A Expense | $41M | 8/16 |
| Cost of Goods Sold | $46M | 11/24 |
| Metric | NAGE | Rank |
|---|---|---|
| Shares Outstanding | 79M | – |
| Net Income Growth | -9.8% | 2/5 |
| EPS Growth | 13.3% | 2/7 |
| Total Current Assets | $98M | 91.8% of assets |
| Cash & Short-term Investments | $67M | 62.7% of assets |
| Accounts Receivable | $9M | 8.1% of assets |
| Inventory | $21M | 19.4% of assets |
| Total Liabilities | $24M | 22.6% of assets |
| Short-term Debt | $6M | 5.3% of assets |
Companies classified under the same SEC industry code as Niagen Bioscience, Inc. (Medicinal Chemicals & Botanical Products): 33 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| NAGE Niagen Bioscience, Inc. | ▶ | $197M |
| DFTX Definium Therapeutics, Inc. | ▲ | $4.31B |
| TRLV Trulieve Cannabis Corp. | ▲ | $1.93B |
| CRON Cronos Group Inc. | ▶ | $1.18B |
| TLRY Tilray Brands, Inc. | ▼ | $414M |
| SNDL Sndl Inc. | ▶ | $322M |
| CGC Canopy Growth Corp | ▶ | $302M |
| GLAS Glass House Brands Inc. | ▼ | $301M |
| USNA Usana Health Sciences Inc | ▼ | $287M |
| ACB Aurora Cannabis Inc | ▶ | $253M |
| MDWD Mediwound Ltd. | ▶ | $152M |
| AAWH Ascend Wellness Holdings, Inc. | ▲ | $80M |
| FTLF Fitlife Brands, Inc. | ▲ | $79M |
| BTMD Biote Corp. | ▲ | $35M |
| RAPH Raphael Pharmaceutical Inc. | ▼ | $30M |
| CHUC Charlie's Holdings, Inc. | ▼ | $27M |
| MRMD Marimed Inc. | ▲ | $24M |
| CFOO China Foods Holdings Ltd. | ▼ | $21M |
| MTEX Mannatech Inc | ▲ | $14M |
| ADIA Adia Med, Inc. | ▲ | $13M |
| GLUC Glucose Health, Inc. | ▼ | $9M |
| NAII Natural Alternatives International Inc | ▲ | $7M |
| BON Bon Natural Life Ltd | ▶ | $7M |
| PLSH Panacea Life Sciences Holdings, Inc. | ▲ | $6M |
| CYAN Cyanotech Corp | ▲ | $5M |
| IMCC Im Cannabis Corp. | ▼ | $2M |
| AIBT Aibotics, Inc. | ▼ | $2M |
| NPHC Nutra Pharma Corp | ▼ | $720K |
| MEHA Functional Brands Inc. | ▼ | $290K |
| CBDY Target Group Inc. | ▼ | N/A |
| HYEX Healthy Extracts Inc. | ▶ | N/A |
| NTRR Neutra Corp. | ▼ | N/A |
| SNYRQ Synergy Chc Corp. | ▼ | N/A |
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A live webcast will be held on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Standard Time (1:30 p.m. Pacific Standard Time) to discuss Niagen Bioscience’s third-quarter financial results and ...
Valter Pinto - Kanan, Corbin, Schupak & Aronow, Inc. Kanan, Corbin, Schupak & Aronow, Inc. Good morning, everyone, and welcome to the Niagen Bioscience Fireside Chat. Thank you all for joining us ...
On Oct. 16, 2026, NAGE is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5184 stocks scored that day.
For NAGE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 59.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 37.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Niagen Bioscience, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
33 issuers in our coverage, NAGE included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Canopy Growth Corp (CGC).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.